In the News

Cognoa logo.

Cognoa CEO and CMO Presenting at Digital Medicine & Medtech Showcase 2020 and Innovator MD Global Summit in San Francisco

PALO ALTO, Calif.- January 6, 2020—Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that senior executives will be speaking at two healthcare innovation and investor conferences in San Francisco. ● Brent Vaughan, CEO and co-founder of Cognoa, will provide an update on the company’s milestones and strategy at the Digital Medicine & Medtech Showcase™ 2020,…

How AI can overcome gender bias in autism diagnosis and treatment

Researchers and advocates have convincingly shown that the wide gap in diagnoses between boys and girls isn’t simply a matter of boys being significantly more likely to be on the autism spectrum. By DAVID HAPPEL Statistically, boys are four times as likely as girls to receive a diagnosis of autism spectrum disorder (ASD). But that’s not because boys are four times as likely to have ASD. According…

Home Together: Navigating COVID-19 and Disrupted Routines With Your ASD Child

Even as households worldwide self-isolate to help curb the spread of the novel coronavirus, we’re the furthest thing from isolated when it comes to what we’re experiencing—starting from the shared stress and concern we’re feeling amid such significant upheaval and uncertainty. For families with a child on the autism spectrum, these times can be uniquely concerning. Disruption to autism spectrum disorder (ASD)…

Cognoa Appoints Industry Leader David Happel as New Chief Executive Officer

Happel takes up the top job at Cognoa after over 25 years of successfully commercializing medical products and as a leader in the biotech and biopharma industries.  (Palo Alto, Calif. – March 24, 2020) – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today the appointment of David Happel as Chief Executive Officer. Cognoa’s former CEO…

Can AI Help With Autism Diagnosis?

An Interview with Cognoa’s CEO Brent Vaughan In the US, one in five children are living with a diagnosable behavioral health disorder; however, only 21% of those children who are diagnosed receive needed treatment. Often, parents have to wait one to three years to receive a proper and accurate diagnosis, and an individualized treatment plan for their child. For the last 15 years, the average…

Multi-modular AI Approach to Streamline Autism Diagnosis in Young Children

Halim Abbas, Ford Garberson, Stuart Liu-Mayo, Eric Glover & Dennis P. Wall  Scientific Reports volume 10, Article number: 5014 (2020) Cite this article 2 Altmetric | Metricsdetails Abstract Autism has become a pressing healthcare challenge. The instruments used to aid diagnosis are time and labor expensive and require trained clinicians to administer, leading to long wait times for at-risk children. We present a multi-modular, machine learning-based assessment of autism comprising three complementary modules…

Cognoa Appoints Dr. Colleen Kraft Senior Medical Director of Clinical Adoption

AAP 2018 Past President Joins Cognoa to Improve the Standard of Care for Children with Autism Through Greater Pediatrician Adoption of Digital Prescription Apps (Palo Alto, Calif.– March 5, 2020) – Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that renowned pediatrician and 2018 Past President of the American Academy of Pediatrics (AAP), Dr. Colleen…

This shows a photo of Brent Vaughan CEO of Cognoa.

Cognoa CEO to Participate in the Cowen and Company 40th Annual Healthcare Conference

PALO ALTO, Calif. — February 26, 2020 — Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that CEO, Brent Vaughan, will participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference with executives from Akili Interactive Labs, Click Therapeutics and Pear Therapeutics. The panel will take place at 1:30…

Location

Social